Aemetis (NASDAQ:AMTX) Stock Price Expected to Rise, UBS Group Analyst Says

Aemetis (NASDAQ:AMTX - Free Report) had its target price boosted by UBS Group from $2.20 to $3.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the specialty chemicals company's stock.

Several other brokerages have also recently commented on AMTX. HC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Aemetis in a research note on Friday, March 14th. Ascendiant Capital Markets raised their target price on shares of Aemetis from $19.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, June 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $13.63.

Aemetis Price Performance

AMTX traded up $0.49 on Monday, reaching $3.11. 1,802,944 shares of the stock were exchanged, compared to its average volume of 792,317. The company's 50-day moving average price is $1.82 and its 200 day moving average price is $2.00. The firm has a market capitalization of $171.92 million, a PE ratio of -1.66 and a beta of 1.57. Aemetis has a fifty-two week low of $1.22 and a fifty-two week high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.08). The firm had revenue of $42.89 million during the quarter, compared to analysts' expectations of $59.35 million. During the same period last year, the firm posted ($0.58) EPS. As a group, equities analysts forecast that Aemetis will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aemetis

A number of large investors have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in shares of Aemetis during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC boosted its holdings in Aemetis by 128.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock worth $28,000 after buying an additional 5,859 shares during the last quarter. Voya Investment Management LLC purchased a new stake in Aemetis during the 4th quarter worth approximately $28,000. Intech Investment Management LLC purchased a new stake in Aemetis during the 4th quarter worth approximately $46,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Aemetis by 16.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company's stock valued at $103,000 after acquiring an additional 5,281 shares during the last quarter. Institutional investors and hedge funds own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.